Welcome to our dedicated page for Tectonic Therapeutic SEC filings (Ticker: TECX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tectonic Therapeutic, Inc. (NASDAQ: TECX) SEC filings page brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tectonic is a clinical-stage biotechnology company focused on GPCR-targeted biologic medicines, and its filings provide structured insight into financial results, clinical development updates and corporate events.
Investors can use this page to access Form 10‑Q and Form 10‑K reports, which contain detailed discussions of Tectonic’s research and development activities, risk factors, and financial statements. For a company advancing programs such as TX45 in Group 2 pulmonary hypertension and PH‑ILD, and TX2100 for Hereditary Hemorrhagic Telangiectasia, these periodic reports explain how clinical trial progress and pipeline strategy relate to operating expenses and liquidity.
The page also surfaces Form 8‑K current reports, where Tectonic discloses material events such as quarterly financial results, positive topline clinical data, updated corporate presentations, and other significant announcements. These filings often reference attached press releases and slide decks that elaborate on trial designs, endpoints, and topline outcomes.
In addition, users can review Section 16 filings such as Form 4, which report changes in beneficial ownership by directors, officers, and other insiders, as well as proxy materials that discuss governance and executive compensation. Stock Titan’s platform layers AI-powered summaries on top of these documents to highlight key points, explain technical language, and help readers quickly understand the implications of lengthy filings without replacing the underlying source documents.
Together, the TECX SEC filings and AI summaries give a structured view of how Tectonic communicates its financial condition, clinical-stage risks, and strategic focus on GPCR-targeted biologics to regulators and investors.
Tectonic Therapeutic, Inc. filed a current report to note that it announced financial results for the quarter ended September 30, 2025 and shared a general business update on November 6, 2025. These details are contained in a press release furnished as an exhibit to the report.
Tectonic Therapeutic (TECX) reported a communications update. The company posted a presentation titled “TX45 Phase 1b (Part B) PH-HFrEF Data Release Single Dose Hemodynamic Trial” and issued a press release announcing positive topline data from the Phase 1b Part B clinical trial of TX45 in patients with Group 2 pulmonary hypertension in HFrEF.
The presentation is furnished as Exhibit 99.1, and the press release is furnished as Exhibit 99.2 and, other than the quotes contained therein, is incorporated by reference. No financial results or transaction terms were disclosed in this update.
Tectonic Therapeutic insider filing: Marc Schwabish, the company's Chief Business Officer and a director, reported equity awards on 09/25/2025. He received 4,210 restricted stock units (RSUs) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, contingent on continued service. He was also granted an employee stock option for 7,650 shares with a $14.71 exercise price that vests in 48 equal monthly installments beginning 10/25/2025 and expires 09/24/2035. The reported shares and options are held directly and the RSUs were issued at no cash price.
Tectonic Therapeutic insider Peter McNamara, the company's Chief Scientific Officer and a director, reported equity awards on 09/25/2025. He was granted 4,550 restricted stock units (RSUs) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, and an employee stock option to purchase 8,260 shares at an exercise price of $14.71 per share that vests monthly over 48 months beginning 10/25/2025 and expires 09/24/2035. After these grants, McNamara directly beneficially owns 33,879 shares and 8,260 option shares underlying the option.
Insider grant and option award reported. Tectonic Therapeutic CFO Daniel Lochner acquired 5,430 restricted stock units (RSUs) on 09/25/2025 that convert one-for-one into common stock and vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, contingent on continued service. He also received an employee stock option to buy 9,860 shares with a $14.71 exercise price, exercisable beginning 09/24/2025 and expiring 09/24/2035; the option vests monthly over 48 months starting 10/25/2025. Following the transactions, Mr. Lochner beneficially owns 28,121 shares (corrected from a prior filing amount).
Marcella K. Ruddy, Chief Medical Officer of Tectonic Therapeutic, Inc. (TECX), received equity awards on 09/25/2025. The filing shows a grant of 5,370 restricted stock units (each convertible to one share) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, subject to continued service. An employee stock option with a $14.71 exercise price covering 9,750 shares was also granted on 09/25/2025; those options vest in 48 equal monthly installments beginning 10/25/2025 and expire 09/24/2035. After these transactions, Ms. Ruddy beneficially owns 55,311 shares. The Form 4 is signed by an attorney-in-fact on 09/29/2025.
Tectonic Therapeutic CEO and director Reicin Alise reported multiple equity awards and holdings on Form 4. The filing shows acquisition on 09/25/2025 of 14,700 restricted stock units (RSUs) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, subject to continued service. The reporting person also holds an employee stock option to buy 26,710 shares at $14.71 per share exercisable beginning 09/25/2025 with expiration 09/24/2035; the option vests monthly over 48 installments starting 10/25/2025.
The report discloses 228,185 shares beneficially owned directly after the RSU acquisition and 124,530 shares held indirectly by the Reicin-Boiarsky Family Trust, where the reporting person may share voting and dispositive power but disclaims beneficial ownership except to extent of pecuniary interest.